Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Identifieur interne : 000069 ( Main/Exploration ); précédent : 000068; suivant : 000070Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Auteurs : P B Chapman [États-Unis] ; C. Robert [France] ; J. Larkin [Royaume-Uni] ; J B Haanen [Pays-Bas] ; A. Ribas [États-Unis] ; D. Hogg [Canada] ; O. Hamid [États-Unis] ; P A Ascierto ; A. Testori [Italie] ; P C Lorigan [Royaume-Uni] ; R. Dummer [Suisse] ; J A Sosman [États-Unis] ; K T Flaherty [États-Unis] ; I. Chang ; S. Coleman ; I. Caro [États-Unis] ; A. Hauschild [Allemagne] ; G A McarthurSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAFV600 mutation-positive metastatic melanoma. We present final OS data from BRIM-3.
DOI: 10.1093/annonc/mdx339
PubMed: 28961848
Affiliations:
- Allemagne, Canada, France, Italie, Pays-Bas, Royaume-Uni, Suisse, États-Unis
- Angleterre, Californie, Canton de Zurich, Grand Londres, Grand Manchester, Hollande-Septentrionale, Illinois, Lombardie, Massachusetts, Schleswig-Holstein, État de New York, Île-de-France
- Amsterdam, Boston, Chicago, Kiel, Londres, Los Angeles, Manchester, Milan, Paris, Zurich
- Université de Manchester, Université de Zurich
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000278
- to stream PubMed, to step Curation: 000276
- to stream PubMed, to step Checkpoint: 000276
- to stream Ncbi, to step Merge: 004F57
- to stream Ncbi, to step Curation: 004F57
- to stream Ncbi, to step Checkpoint: 004F57
- to stream Main, to step Merge: 000064
- to stream Main, to step Curation: 000069
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.</title><author><name sortKey="Chapman, P B" sort="Chapman, P B" uniqKey="Chapman P" first="P B" last="Chapman">P B Chapman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Robert, C" sort="Robert, C" uniqKey="Robert C" first="C" last="Robert">C. Robert</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Institut Gustave Roussy and Paris Sud University, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medicine, Institut Gustave Roussy and Paris Sud University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Larkin, J" sort="Larkin, J" uniqKey="Larkin J" first="J" last="Larkin">J. Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine, The Royal Marsden NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Haanen, J B" sort="Haanen, J B" uniqKey="Haanen J" first="J B" last="Haanen">J B Haanen</name><affiliation wicri:level="3"><nlm:affiliation>Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Ribas, A" sort="Ribas, A" uniqKey="Ribas A" first="A" last="Ribas">A. Ribas</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Hematology and Oncology, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Hematology and Oncology, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hogg, D" sort="Hogg, D" uniqKey="Hogg D" first="D" last="Hogg">D. Hogg</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University Health Network, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name><affiliation wicri:level="3"><nlm:affiliation>The Angeles Clinic and Research Institute, Melanoma Therapeutics, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Angeles Clinic and Research Institute, Melanoma Therapeutics, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ascierto, P A" sort="Ascierto, P A" uniqKey="Ascierto P" first="P A" last="Ascierto">P A Ascierto</name><affiliation><nlm:affiliation>Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples.</nlm:affiliation><wicri:noCountry code="subField">Naples</wicri:noCountry></affiliation></author><author><name sortKey="Testori, A" sort="Testori, A" uniqKey="Testori A" first="A" last="Testori">A. Testori</name><affiliation wicri:level="3"><nlm:affiliation>Melanoma and Sarcoma, Istituto Europeo di Oncologia, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma and Sarcoma, Istituto Europeo di Oncologia, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Lorigan, P C" sort="Lorigan, P C" uniqKey="Lorigan P" first="P C" last="Lorigan">P C Lorigan</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, University of Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Oncology, University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region><settlement type="city">Manchester</settlement></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R" last="Dummer">R. Dummer</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, University of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Dermatology, University of Zurich, Zurich</wicri:regionArea><orgName type="university">Université de Zurich</orgName><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region></placeName></affiliation></author><author><name sortKey="Sosman, J A" sort="Sosman, J A" uniqKey="Sosman J" first="J A" last="Sosman">J A Sosman</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName><wicri:orgArea>Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University</wicri:orgArea></affiliation></author><author><name sortKey="Flaherty, K T" sort="Flaherty, K T" uniqKey="Flaherty K" first="K T" last="Flaherty">K T Flaherty</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Massachusetts General Hospital, Boston.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Medicine, Massachusetts General Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Chang, I" sort="Chang, I" uniqKey="Chang I" first="I" last="Chang">I. Chang</name><affiliation><nlm:affiliation>Department of Biostatistics in Product Development, Biometrics.</nlm:affiliation><wicri:noCountry code="subField">Biometrics</wicri:noCountry></affiliation></author><author><name sortKey="Coleman, S" sort="Coleman, S" uniqKey="Coleman S" first="S" last="Coleman">S. Coleman</name><affiliation><nlm:affiliation>Clinical Department.</nlm:affiliation><wicri:noCountry code="no comma">Clinical Department.</wicri:noCountry></affiliation></author><author><name sortKey="Caro, I" sort="Caro, I" uniqKey="Caro I" first="I" last="Caro">I. Caro</name><affiliation wicri:level="1"><nlm:affiliation>Product Development, Oncology, Genentech Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Product Development, Oncology, Genentech Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name><affiliation><nlm:affiliation>Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne.</nlm:affiliation><wicri:noCountry code="subField">East Melbourne</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28961848</idno><idno type="pmid">28961848</idno><idno type="doi">10.1093/annonc/mdx339</idno><idno type="wicri:Area/PubMed/Corpus">000278</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000278</idno><idno type="wicri:Area/PubMed/Curation">000276</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000276</idno><idno type="wicri:Area/PubMed/Checkpoint">000276</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000276</idno><idno type="wicri:Area/Ncbi/Merge">004F57</idno><idno type="wicri:Area/Ncbi/Curation">004F57</idno><idno type="wicri:Area/Ncbi/Checkpoint">004F57</idno><idno type="wicri:Area/Main/Merge">000064</idno><idno type="wicri:Area/Main/Curation">000069</idno><idno type="wicri:Area/Main/Exploration">000069</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.</title><author><name sortKey="Chapman, P B" sort="Chapman, P B" uniqKey="Chapman P" first="P B" last="Chapman">P B Chapman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Robert, C" sort="Robert, C" uniqKey="Robert C" first="C" last="Robert">C. Robert</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Institut Gustave Roussy and Paris Sud University, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medicine, Institut Gustave Roussy and Paris Sud University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Larkin, J" sort="Larkin, J" uniqKey="Larkin J" first="J" last="Larkin">J. Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine, The Royal Marsden NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Haanen, J B" sort="Haanen, J B" uniqKey="Haanen J" first="J B" last="Haanen">J B Haanen</name><affiliation wicri:level="3"><nlm:affiliation>Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Ribas, A" sort="Ribas, A" uniqKey="Ribas A" first="A" last="Ribas">A. Ribas</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Hematology and Oncology, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Hematology and Oncology, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hogg, D" sort="Hogg, D" uniqKey="Hogg D" first="D" last="Hogg">D. Hogg</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University Health Network, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name><affiliation wicri:level="3"><nlm:affiliation>The Angeles Clinic and Research Institute, Melanoma Therapeutics, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Angeles Clinic and Research Institute, Melanoma Therapeutics, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ascierto, P A" sort="Ascierto, P A" uniqKey="Ascierto P" first="P A" last="Ascierto">P A Ascierto</name><affiliation><nlm:affiliation>Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples.</nlm:affiliation><wicri:noCountry code="subField">Naples</wicri:noCountry></affiliation></author><author><name sortKey="Testori, A" sort="Testori, A" uniqKey="Testori A" first="A" last="Testori">A. Testori</name><affiliation wicri:level="3"><nlm:affiliation>Melanoma and Sarcoma, Istituto Europeo di Oncologia, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma and Sarcoma, Istituto Europeo di Oncologia, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Lorigan, P C" sort="Lorigan, P C" uniqKey="Lorigan P" first="P C" last="Lorigan">P C Lorigan</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, University of Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Oncology, University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region><settlement type="city">Manchester</settlement></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R" last="Dummer">R. Dummer</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, University of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Dermatology, University of Zurich, Zurich</wicri:regionArea><orgName type="university">Université de Zurich</orgName><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region></placeName></affiliation></author><author><name sortKey="Sosman, J A" sort="Sosman, J A" uniqKey="Sosman J" first="J A" last="Sosman">J A Sosman</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName><wicri:orgArea>Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University</wicri:orgArea></affiliation></author><author><name sortKey="Flaherty, K T" sort="Flaherty, K T" uniqKey="Flaherty K" first="K T" last="Flaherty">K T Flaherty</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Massachusetts General Hospital, Boston.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Medicine, Massachusetts General Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Chang, I" sort="Chang, I" uniqKey="Chang I" first="I" last="Chang">I. Chang</name><affiliation><nlm:affiliation>Department of Biostatistics in Product Development, Biometrics.</nlm:affiliation><wicri:noCountry code="subField">Biometrics</wicri:noCountry></affiliation></author><author><name sortKey="Coleman, S" sort="Coleman, S" uniqKey="Coleman S" first="S" last="Coleman">S. Coleman</name><affiliation><nlm:affiliation>Clinical Department.</nlm:affiliation><wicri:noCountry code="no comma">Clinical Department.</wicri:noCountry></affiliation></author><author><name sortKey="Caro, I" sort="Caro, I" uniqKey="Caro I" first="I" last="Caro">I. Caro</name><affiliation wicri:level="1"><nlm:affiliation>Product Development, Oncology, Genentech Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Product Development, Oncology, Genentech Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name><affiliation><nlm:affiliation>Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne.</nlm:affiliation><wicri:noCountry code="subField">East Melbourne</wicri:noCountry></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAFV600 mutation-positive metastatic melanoma. We present final OS data from BRIM-3.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Canada</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Californie</li><li>Canton de Zurich</li><li>Grand Londres</li><li>Grand Manchester</li><li>Hollande-Septentrionale</li><li>Illinois</li><li>Lombardie</li><li>Massachusetts</li><li>Schleswig-Holstein</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Amsterdam</li><li>Boston</li><li>Chicago</li><li>Kiel</li><li>Londres</li><li>Los Angeles</li><li>Manchester</li><li>Milan</li><li>Paris</li><li>Zurich</li></settlement><orgName><li>Université de Manchester</li><li>Université de Zurich</li></orgName></list><tree><noCountry><name sortKey="Ascierto, P A" sort="Ascierto, P A" uniqKey="Ascierto P" first="P A" last="Ascierto">P A Ascierto</name><name sortKey="Chang, I" sort="Chang, I" uniqKey="Chang I" first="I" last="Chang">I. Chang</name><name sortKey="Coleman, S" sort="Coleman, S" uniqKey="Coleman S" first="S" last="Coleman">S. Coleman</name><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Chapman, P B" sort="Chapman, P B" uniqKey="Chapman P" first="P B" last="Chapman">P B Chapman</name></region><name sortKey="Caro, I" sort="Caro, I" uniqKey="Caro I" first="I" last="Caro">I. Caro</name><name sortKey="Flaherty, K T" sort="Flaherty, K T" uniqKey="Flaherty K" first="K T" last="Flaherty">K T Flaherty</name><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name><name sortKey="Ribas, A" sort="Ribas, A" uniqKey="Ribas A" first="A" last="Ribas">A. Ribas</name><name sortKey="Sosman, J A" sort="Sosman, J A" uniqKey="Sosman J" first="J A" last="Sosman">J A Sosman</name></country><country name="France"><region name="Île-de-France"><name sortKey="Robert, C" sort="Robert, C" uniqKey="Robert C" first="C" last="Robert">C. Robert</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Larkin, J" sort="Larkin, J" uniqKey="Larkin J" first="J" last="Larkin">J. Larkin</name></region><name sortKey="Lorigan, P C" sort="Lorigan, P C" uniqKey="Lorigan P" first="P C" last="Lorigan">P C Lorigan</name></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Haanen, J B" sort="Haanen, J B" uniqKey="Haanen J" first="J B" last="Haanen">J B Haanen</name></region></country><country name="Canada"><noRegion><name sortKey="Hogg, D" sort="Hogg, D" uniqKey="Hogg D" first="D" last="Hogg">D. Hogg</name></noRegion></country><country name="Italie"><region name="Lombardie"><name sortKey="Testori, A" sort="Testori, A" uniqKey="Testori A" first="A" last="Testori">A. Testori</name></region></country><country name="Suisse"><region name="Canton de Zurich"><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R" last="Dummer">R. Dummer</name></region></country><country name="Allemagne"><region name="Schleswig-Holstein"><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000069 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000069 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28961848
|texte= Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28961848" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |